WHO has posted the membership of the Guidelines Development Group (GDG) for the upcoming guidelines on the public health response for the prevention of mother-to-child transmission of hepatitis B (HBV) virus infection, which will convene in Geneva, Switzerland, on 9-10 September 2019.
This GDG will review the evidence to make decisions on:
- If antiviral medicines administered during pregnancy are effective and safe to reduce mother to child transmission of hepatitis B virus infection; and
- If HBeAg tests could be an alternative to diagnose high HBV DNA levels to assess eligibility for initiating antiviral therapy during pregnancy to prevent mother to child transmission.
The group will also work to:
- consider key implementation issues for all recommendations; and
- identify key priorities for future research.
Members of the public and interested organizations can view the biographies of these GDG members. They can also inform WHO of their views about any of them by 9 September 2019 by writing to hepatitis@who.int.